Indicators
Indicators
Value
Direction
MACD(12,26,9)
-7.810
Neutral
RSI(14)
53.447
Neutral
STOCH(KDJ)(9,3,3)
47.559
Buy
ATR(14)
17.946
High Vlolatility
CCI(14)
-3.748
Neutral
Williams %R
53.054
Neutral
TRIX(12,20)
-0.009
Sell
StochRSI(14)
100.000
Buy
Search
Krystal Biotech Inc
KRYSAdd to Watchlist
352.060USD
+16.870+5.03%
Close 07-27 16:00（ET）Quotes delayed by 15 min
10.28BMarket Cap
45.45P/E TTM
View Detailed Chart
TradingKey ChartIntraday
1m
30m
1h
D
W
M
D
Today
+5.03%
5 Days
+3.79%
1 Month
-5.42%
6 Months
+26.93%
Year to Date
+42.80%
1 Year
+138.51%
Key Figures
339.100Open
358.000High
537.30KVolume
45.45P/E TTM
33.54P/E Dynamic
--Dividend TTM
1.84%Turnover Ratio
335.190Prev. Close
334.375Low
137.47MTurnover
115.27P/E Static
8.43P/B
0.00%Div Yield TTM
18.21%ROA
319.48052wk High
0.43Volume Ratio
89.16MNet Profit
29.19MShares
7.7464EPS TTM
0.52Beta
19.90%ROE
123.03452wk Low
7.05%Amplitude
94.57%Gross Margin
10.28BMarket Cap
-4.15Reward/Risk
2.40%Risk Rate
TradingKey Stock Score of Krystal Biotech Inc
Currency: USD Updated: 2026-07-27Key Insights
Krystal Biotech Inc's fundamentals are relatively very healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 4 out of 386 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 353.21.In the medium term, the stock price is expected to trend up.Despite a weak stock market performance over the past month, the company shows strong fundamentals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Krystal Biotech Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Positive
Krystal Biotech Inc Highlights
StrengthsRisks
Krystal Biotech, Inc. is an integrated, commercial-stage biotechnology company. The Company is focused on the discovery, development, and commercialization of genetic medicines to treat diseases with high unmet medical needs. Its product candidates in various stages of clinical and preclinical development include KB407, KB408, KB707, KB105, KB801, KB803, KB304 and KB301. Its commercial product, VYJUVEK, is a redosable gene therapy, and a genetic medicine approved in the United States and Europe for the treatment of dystrophic epidermolysis bullosa. KB407 is being developed for the treatment of Cystic Fibrosis. KB408 is being developed for the treatment of Alpha-1 Antitrypsin Deficiency, a rare lung disease. KB707 is being developed for the treatment of solid tumors. KB105 is being developed for TGM1-Deficient Autosomal Recessive Congenital Ichthyosis. KB803 is a redosable eye drop formulation of B-VEC, designed for the treatment of ocular complications.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 667.53% year-on-year.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 389.13M.
Fairly Valued
The company’s latest PE is 45.42, at a medium 3-year percentile range.
Institutional Buying
The latest institutional holdings are 32.60M shares, increasing 4.36% quarter-over-quarter.
Held by Ray Dalio
Star Investor Ray Dalio holds 39.07K shares of this stock.
Higher Market Activity
The company has more investor interest, with a 20-day turnover ratio of 0.90.
Analyst Rating
Based on
13
analysts
Buy
Current Rating
353.212
Target Price
+5.38%
Upside Space
Krystal Biotech Inc News
More news coming soon, stay tuned...
Earnings Forecast
Analyst Rating
Based on
13
analysts
Buy
Current Rating
353.212
Target Price
+5.38%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
160
Total
6
Median
9
Average
Company name
Ratings
Analysts
Krystal Biotech Inc
KRYS
13
Biogen Inc
BIIB
38
Amgen Inc
AMGN
37
Eli Lilly and Co
LLY
34
AbbVie Inc
ABBV
33
Pfizer Inc
PFE
32
1
2
3
...
32
Indicators
Moving Average
Indicators
Value
Direction
MA5
338.074
Buy
MA10
341.591
Buy
MA20
356.577
Sell
MA50
332.804
Buy
MA100
299.797
Buy
MA200
268.498
Buy
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Krystal Biotech Inc Info
Krystal Biotech, Inc. is an integrated, commercial-stage biotechnology company. The Company is focused on the discovery, development, and commercialization of genetic medicines to treat diseases with high unmet medical needs. Its product candidates in various stages of clinical and preclinical development include KB407, KB408, KB707, KB105, KB801, KB803, KB304 and KB301. Its commercial product, VYJUVEK, is a redosable gene therapy, and a genetic medicine approved in the United States and Europe for the treatment of dystrophic epidermolysis bullosa. KB407 is being developed for the treatment of Cystic Fibrosis. KB408 is being developed for the treatment of Alpha-1 Antitrypsin Deficiency, a rare lung disease. KB707 is being developed for the treatment of solid tumors. KB105 is being developed for TGM1-Deficient Autosomal Recessive Congenital Ichthyosis. KB803 is a redosable eye drop formulation of B-VEC, designed for the treatment of ocular complications.
Ticker SymbolKRYS
CompanyKrystal Biotech Inc
CEOKrishnan (Krish S)
Websitehttps://www.krystalbio.com/
Shareholders
Related Instruments
+0.16%
+0.98%
+0.25%
-0.96%
-0.23%
+0.70%
+0.06%
+1.88%
+0.92%
+0.49%
+0.76%
+0.34%
+1.52%
+1.21%
+1.18%
0.00%
+1.72%
-3.24%
+1.16%
+0.57%Popular Instruments
52250.200
+11.200 (+0.02%)
27798.700
-257.300 (-0.92%)
7397.600
-20.800 (-0.28%)
14704.000
-409.000 (-2.71%)
62468.000
-1337.000 (-2.10%)
6297.700
-13.600 (-0.21%)
80.520
-0.817 (-1.00%)
336.900
+3.880 (+1.17%)
196.560
-10.280 (-4.97%)
4048.350
-28.090 (-0.69%)
FAQs
What is the current price of Krystal Biotech Inc (KRYS)?
The current price of Krystal Biotech Inc (KRYS) is 352.06.
What is the symbol of Krystal Biotech Inc?
The ticker symbol of Krystal Biotech Inc is KRYS.
What is the 52-week high of Krystal Biotech Inc?
The 52-week high of Krystal Biotech Inc is 319.48.
What is the 52-week low of Krystal Biotech Inc?
The 52-week low of Krystal Biotech Inc is 123.03.
What is the market capitalization of Krystal Biotech Inc?
The market capitalization of Krystal Biotech Inc is 10.28B.
Is Krystal Biotech Inc (KRYS) currently rated as Buy, Hold, or Sell?
According to analysts, Krystal Biotech Inc (KRYS) has an overall rating of Buy, with a price target of 353.21.
What is the Earnings Per Share (EPS TTM) of Krystal Biotech Inc (KRYS)?
The Earnings Per Share (EPS TTM) of Krystal Biotech Inc (KRYS) is 7.08.